464 related articles for article (PubMed ID: 11948271)
1. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis.
Martin DF; Sierra-Madero J; Walmsley S; Wolitz RA; Macey K; Georgiou P; Robinson CA; Stempien MJ;
N Engl J Med; 2002 Apr; 346(15):1119-26. PubMed ID: 11948271
[TBL] [Abstract][Full Text] [Related]
2. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. Syntex Cooperative Oral Ganciclovir Study Group.
Drew WL; Ives D; Lalezari JP; Crumpacker C; Follansbee SE; Spector SA; Benson CA; Friedberg DN; Hubbard L; Stempien MJ
N Engl J Med; 1995 Sep; 333(10):615-20. PubMed ID: 7637721
[TBL] [Abstract][Full Text] [Related]
3. Valganciclovir.
Curran M; Noble S
Drugs; 2001; 61(8):1145-50 ; discussion 1151-2. PubMed ID: 11465875
[TBL] [Abstract][Full Text] [Related]
4. Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis.
Boivin G; Gilbert C; Gaudreau A; Greenfield I; Sudlow R; Roberts NA
J Infect Dis; 2001 Dec; 184(12):1598-602. PubMed ID: 11740736
[TBL] [Abstract][Full Text] [Related]
5. Oral ganciclovir for cytomegalovirus retinitis in patients with AIDS: results of two randomized studies.
Squires KE
AIDS; 1996 Dec; 10 Suppl 4():S13-8. PubMed ID: 9110065
[TBL] [Abstract][Full Text] [Related]
6. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group.
Martin DF; Kuppermann BD; Wolitz RA; Palestine AG; Li H; Robinson CA
N Engl J Med; 1999 Apr; 340(14):1063-70. PubMed ID: 10194235
[TBL] [Abstract][Full Text] [Related]
7. Valganciclovir: oral prevention and treatment of cytomegalovirus in the immunocompromised host.
Freeman RB
Expert Opin Pharmacother; 2004 Sep; 5(9):2007-16. PubMed ID: 15330737
[TBL] [Abstract][Full Text] [Related]
8. A safety study of oral valganciclovir maintenance treatment of cytomegalovirus retinitis.
Lalezari J; Lindley J; Walmsley S; Kuppermann B; Fisher M; Friedberg D; Lalonde R; Matheron S; Nieto L; Torriani FJ; Van Syoc R; Sutton MA; Buhles W; Stempien MJ;
J Acquir Immune Defic Syndr; 2002 Aug; 30(4):392-400. PubMed ID: 12138345
[TBL] [Abstract][Full Text] [Related]
9. Valganciclovir: new preparation. CMV retinitis: a simpler, oral treatment.
Prescrire Int; 2003 Aug; 12(66):133-5. PubMed ID: 12906021
[TBL] [Abstract][Full Text] [Related]
10. Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. The Ganciclovir Implant Study Group.
Musch DC; Martin DF; Gordon JF; Davis MD; Kuppermann BD
N Engl J Med; 1997 Jul; 337(2):83-90. PubMed ID: 9211677
[TBL] [Abstract][Full Text] [Related]
11. High dose oral ganciclovir treatment for cytomegalovirus retinitis.
Lalezari JP; Friedberg DN; Bissett J; Giordano MF; Hardy WD; Drew WL; Hubbard LD; Buhles WC; Stempien MJ; Georgiou P; Jung DT; Robinson CA;
J Clin Virol; 2002 Feb; 24(1-2):67-77. PubMed ID: 11744430
[TBL] [Abstract][Full Text] [Related]
12. Valganciclovir for the prevention and treatment of cytomegalovirus disease in immunocompromised hosts.
Razonable RR; Paya CV
Expert Rev Anti Infect Ther; 2004 Feb; 2(1):27-41. PubMed ID: 15482169
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of valganciclovir and ganciclovir in renal impairment.
Czock D; Scholle C; Rasche FM; Schaarschmidt D; Keller F
Clin Pharmacol Ther; 2002 Aug; 72(2):142-50. PubMed ID: 12189361
[TBL] [Abstract][Full Text] [Related]
14. Cytomegalovirus retinitis in AIDS patients: a comparative study of intravenous and oral ganciclovir as maintenance therapy.
Danner SA; Matheron S
AIDS; 1996 Dec; 10 Suppl 4():S7-11. PubMed ID: 9110064
[TBL] [Abstract][Full Text] [Related]
15. Treatment of cytomegalovirus retinitis with oral valganciclovir in an acquired immunodeficiency syndrome patient unresponsive to combination antiretroviral therapy.
Lee CH; Bright DC; Ferrucci S
Optometry; 2006 Apr; 77(4):167-76. PubMed ID: 16567278
[TBL] [Abstract][Full Text] [Related]
16. Valganciclovir: A new oral alternative for cytomegalovirus retinitis in human immunodeficiency virus-seropositive individuals.
Segarra-Newnham M; Salazar MI
Pharmacotherapy; 2002 Sep; 22(9):1124-8. PubMed ID: 12222548
[TBL] [Abstract][Full Text] [Related]
17. Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. The Cytomegalovirus Retreatment Trial. The Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group.
Arch Ophthalmol; 1996 Jan; 114(1):23-33. PubMed ID: 8540847
[TBL] [Abstract][Full Text] [Related]
18. Valganciclovir: a new treatment for cytomegalovirus retinitis.
Marco M
BETA; 2002; 15(1):19-21. PubMed ID: 12141246
[No Abstract] [Full Text] [Related]
19. Treating HIV-associated cytomegalovirus retinitis with oral valganciclovir and intra-ocular ganciclovir by primary HIV clinicians in southern Myanmar: a retrospective analysis of routinely collected data.
Murray J; Hilbig A; Soe TT; Ei WLSS; Soe KP; Ciglenecki I
BMC Infect Dis; 2020 Nov; 20(1):842. PubMed ID: 33187478
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers.
Brown F; Banken L; Saywell K; Arum I
Clin Pharmacokinet; 1999 Aug; 37(2):167-76. PubMed ID: 10496303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
